IPO - Moleculin Biotech, Inc.

Form Type: S-1

Filing Date: 2025-03-31

Corporate Action: Ipo

Type: New

Accession Number: 000143774925010255

Filing Summary: Moleculin Biotech, Inc. has filed a registration statement on Form S-1 with the SEC for the purpose of issuing and reselling up to 18,199,198 shares of common stock. This total includes 6,542,058 shares which are issuable upon exercise of Series D common stock purchase warrants and 11,657,140 shares obtainable through Inducement Warrants. The Inducement Warrants allow a holder to purchase up to 200% of shares in relation to certain existing warrants they will exercise. Significant details include a reduced exercise price of $1.00 per share for these existing warrants. The Series D Warrants will be exercisable at a price of $1.07 per share pending shareholder approval, which is being sought in a special meeting scheduled for April 9, 2025. The company emphasizes that it is not selling any common stock under this prospectus and will not benefit financially from the selling stockholder’s transactions. The common stock is listed on Nasdaq under the symbol "MBRX". The registration statement includes risks associated with investing in Moleculin's securities and declares the date of registration as March 31, 2025.

Document Link: View Document

Form Type: 424B5

Filing Date: 2025-02-26

Corporate Action: Ipo

Type: New

Accession Number: 000143774925005173

Filing Summary: Moleculin Biotech, Inc. is offering 1,150,000 shares of its common stock at a price of $1.07 per share to institutional investors through a registration statement filed on July 1, 2024, highlighted in the prospectus supplement dated February 25, 2025. Concurrently, the company is placing warrants to purchase up to 6,542,058 shares of common stock. The offering includes 2,121,029 pre-funded warrants for certain investors, exercisable for one share at a price of $0.001 per share. The warrants exercise is contingent upon stockholder approval and will expire five years following such approval. The total gross proceeds from the offering are projected to be approximately $3.5 million, before expenses, and the proceeds will be used for corporate purposes. The final delivery of securities is expected on February 26, 2025. A notable aspect is the 7.0% fee to Roth Capital Partners LLC, the placement agent for the offering, emphasizing the company's concerted efforts to raise capital efficiently through structured offerings.

Document Link: View Document

Form Type: S-1/A

Filing Date: 2025-02-11

Corporate Action: Ipo

Type: Update

Accession Number: 000143774925003357

Filing Summary: Moleculin Biotech, Inc. has filed an amendment to its registration statement under the Securities Act of 1933 on Form S-1/A for the proposed sale of up to 23,809,524 shares of common stock, along with accompanying Series C and Series D warrants. The offering price is set at an assumed public offering price of $0.84 per share, based on the last reported sale price on February 6, 2025. This is part of a broader strategy to raise funds for clinical trials, especially for its lead drug candidate Annamycin, intended for treatment of patients with Acute Myeloid Leukemia (AML). The company is focusing on conducting a pivotal Phase 3 trial for Annamycin in combination with Cytarabine as a treatment for patients who are refractory to or have relapsed after prior therapy. The document outlines the solicitation for market offerings, risk factors associated with the investment, and management’s plans for future clinical development. A waiver and consent agreement was entered into on February 9, 2025, with an investor, allowing for adjustments related to warrant exercise prices and payment structures. The anticipated commencement of the offering is immediate upon effectiveness of the registration. The document emphasizes the non-standard issuance of pre-funded warrants for certain purchasers to avoid exceeding beneficial ownership limitations.

Document Link: View Document

Form Type: S-1/A

Filing Date: 2025-02-10

Corporate Action: Ipo

Type: Update

Accession Number: 000143774925003210

Filing Summary: Moleculin Biotech, Inc. is filing Amendment No. 2 to their Form S-1 registration statement to register the offering of up to 23,809,524 shares of common stock and accompanying Series C and D warrants for purchase of additional shares. The offering price is assumed to be $0.84 per share, based on the last reported sale price on the Nasdaq. The company is focused on advancing its lead drug Annamycin through its Phase 3 clinical trials for treating acute myeloid leukemia (AML) and has engaged Roth Capital Partners as its placement agent. They are also offering pre-funded warrants to control ownership levels at 4.99% or 9.99%. This update highlights specific details regarding the structure and offering of its common stock and warrants, as well as the ongoing phase trials for Annamycin, including the planned Phase 3 “MIRACLE” trial. The document includes detailed information on the company's clinical development strategy, potential selling price adjustments, regulatory considerations, and outlines the risks associated with the investment.

Document Link: View Document

Form Type: S-1/A

Filing Date: 2025-01-29

Corporate Action: Ipo

Type: New

Accession Number: 000143774925002083

Filing Summary: Moleculin Biotech, Inc. is filing an amendment to its registration statement on Form S-1 for a public offering of shares of common stock and warrants. The company is seeking to sell up to 4,761,905 shares of common stock accompanied by Series C and Series D warrants to purchase additional shares at a combined public offering price of $1.68 per share. The offering aims to raise capital for ongoing clinical trials, specifically for their lead drug candidate, Annamycin, which is in advanced stages of clinical development for treating Acute Myeloid Leukemia (AML). The document outlines the potential offerings, pricing conditions, details about the underlying securities, and expected termination of the offering on February 14, 2025. Additionally, it discusses the rigorous design of the ongoing Phase 3 MIRACLE trial for AML and the company's overall strategic focus on the development of Annamycin and its related technologies. The offering is characterized as a best-efforts method where no minimum proceeds are guaranteed, highlighting potential risks for investors based on the company's ability to sell all offered securities.

Document Link: View Document